BiondVax Pharma: U.S. shares plunge as flu vaccine fails to meet efficacy goals
23/10/2020 17:42
** Israeli vaccine developer's U.S.-listed shares BVXV.O
slump as much as 90.5% to $3.60, hitting over a 3-1/2-year low
** BVXV stock was halted multiple times due to volatility
during trading hours on Friday
** BiondVax's universal flu vaccine candidate failed to meet
main efficacy goals in a late-stage trial urn:newsml:reuters.com:*:nPn947V0fa
** Co says vaccine was safe but did not reduce flu illness
and severity in study's vaccinated group
** BVXV had started late-stage trial for the vaccine in 2018
** Including session's losses, U.S.-listed shares of BVXV
have fallen ~61% YTD
(Reporting by Bhanvi Satija)
((Bhanvi.Satija@thomsonreuters.com;))